{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:07:08Z","timestamp":1790269628197,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Celiac disease (CD) is a common autoimmune disease affecting around 1% of the population. It consists of an immune-mediated enteropathy, triggered by gluten exposure in susceptible patients. All patients with CD, irrespective of the presence of symptoms, must endure a lifelong gluten-free diet (GFD). This is not an easy task due to a lack of awareness of the gluten content in foods and the extensive incorporation of gluten in processed foods. Furthermore, a GFD imposes a sense of limitation and might be associated with decreased quality of life in CD patients. This results in gluten contamination in the diet of four out of five celiac patients adhering to a GFD. Furthermore, one in three adult patients will report persistent symptoms and two in three will not achieve full histological recovery when on a GFD. In recent years, there has been extensive research conducted in the quest to find the holy grail of pharmacological treatment for CD. This review will present a concise description of the current rationale and main clinical trials related to CD drug therapy.<\/jats:p>","DOI":"10.3390\/ijms24020945","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:31:44Z","timestamp":1672810304000},"page":"945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["New Developments in Celiac Disease Treatment"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7860","authenticated-orcid":false,"given":"Mariana Verdelho","family":"Machado","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Hospital de Vila Franca de Xira, Estrada Carlos Lima Costa, N\u00aa 2, 2600-009 Vila Franca de Xira, Portugal"},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Avenida Prof. Egas Moniz, 1649-028 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000514716","article-title":"Celiac disease revisited","volume":"29","author":"Calado","year":"2021","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00251-019-01141-w","article-title":"Update 2020: Nomenclature and listing of celiac disease\u2013relevant gluten epitopes recognized by CD4+ T cells","volume":"72","author":"Sollid","year":"2020","journal-title":"Immunogenetics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global Prevalence of Celiac Disease: Systematic Review and Meta-Analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.2017.9730","article-title":"Celiac disease and nonceliac gluten sensitivity: A review","volume":"318","author":"Leonard","year":"2017","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.14309\/ajg.0000000000000665","article-title":"Overall and Cause-Specific Mortality in Adult Celiac Disease and Dermatitis Herpetiformis Diagnosed in the 21st Century","volume":"115","author":"Koskinen","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jama.2020.1943","article-title":"Association Between Celiac Disease and Mortality Risk in a Swedish Population","volume":"323","author":"Lebwohl","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/2050640618814662","article-title":"Mortality in people with coeliac disease: Long-term follow-up from a Scottish cohort","volume":"7","author":"Quarpong","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(01)05554-4","article-title":"Mortality in patients with coeliac disease and their relatives: A cohort study","volume":"358","author":"Corrao","year":"2001","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ajg.2010.10","article-title":"Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free die","volume":"105","author":"Rahim","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2009.04053.x","article-title":"Systematic review: Adherence to a gluten-free diet in adult patients with coeliac disease","volume":"30","author":"Hall","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hollon, J.R., Cureton, P.A., Martin, M.L., Puppa, E.L.L., and Fasano, A. (2013). Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patien. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-40"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2019.12.016","article-title":"Most Patients with Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten","volume":"158","author":"Silvester","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_13","first-page":"A5307","article-title":"Epidemiologic and therapeutic aspects of refractory coeliac disease\u2014A systematic review","volume":"63","author":"Rowinski","year":"2016","journal-title":"Dan. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2022.07.086","article-title":"AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review","volume":"163","author":"Green","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/apt.16846","article-title":"Review article: Therapeutic targets for the pharmacologic management of coeliac disease\u2014The future beyond a gluten-free diet","volume":"55","author":"Klonarakis","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.smim.2015.11.001","article-title":"Celiac disease: Autoimmunity in response to food antigen","volume":"27","author":"Stamnaes","year":"2015","journal-title":"Semin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI30253","article-title":"Celiac disease: Pathogenesis of a model immunogenetic disease","volume":"117","author":"Kagnoff","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3748\/wjg.v28.i1.154","article-title":"Current guidelines for the management of celiac disease: A systematic review with comparative analysis","volume":"28","author":"Raiteri","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cgh.2015.10.024","article-title":"Features and Progression of Potential Celiac Disease in Adults","volume":"14","author":"Volta","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13223-021-00557-y","article-title":"Anti-ganglioside antibodies and celiac disease","volume":"17","author":"Granito","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2005.11.013","article-title":"Anti-ganglioside antibodies in coeliac disease with neurological disorders","volume":"38","author":"Volta","year":"2006","journal-title":"Dig. Liver Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1053\/j.gastro.2007.04.070","article-title":"Sera of Patients with Celiac Disease and Neurologic Disorders Evoke a Mitochondrial-Dependent Apoptosis In Vitro","volume":"133","author":"Cervio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1590-8658(00)80354-0","article-title":"Prevalence of silent coeliac disease in atopics","volume":"32","author":"Zauli","year":"2000","journal-title":"Dig. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1590-8658(01)80014-1","article-title":"Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin","volume":"33","author":"Volta","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000048840","article-title":"Coeliac Disease in Patients with Autoimmune Thyroiditis","volume":"64","author":"Volta","year":"2001","journal-title":"Digestion"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MPG.0000000000001420","article-title":"Extraintestinal Manifestations of Celiac Disease: Effectiveness of the Gluten-Free Diet","volume":"65","author":"Jericho","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/jnnp.74.9.1221","article-title":"Dietary treatment of gluten ataxia","volume":"74","author":"Hadjivassiliou","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2021.03.003","article-title":"Celiac Disease in Children: An Association with Drug-Resistant Epilepsy","volume":"120","author":"Swartwood","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.12809","article-title":"Cognitive impairment in coeliac disease improves on a gluten-free diet and correlates with histological and serological indices of disease severity","volume":"40","author":"Lichtwark","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2036.2005.02619.x","article-title":"Fatigue in adult coeliac disease","volume":"22","author":"Siniscalchi","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s10620-005-9054-4","article-title":"Peripheral Neurological Disturbances, Autonomic Dysfunction, and Antineuronal Antibodies in Adult Celiac Disease before and after a Gluten-Free Diet","volume":"51","author":"Tursi","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0140-6736(73)91539-0","article-title":"Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal","volume":"301","author":"Fry","year":"1973","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Passali, M., Josefsen, K., Frederiksen, J.L., and Antvorskov, J.C. (2020). Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases. Nutrients, 12.","DOI":"10.3390\/nu12082316"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1399-3038.2005.00309.x","article-title":"Chronic urticaria and associated coeliac disease in children: A case-control study","volume":"16","author":"Caminiti","year":"2005","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MCG.0b013e318074dd98","article-title":"Oral Manifestations of Celiac Disease","volume":"42","author":"Pastore","year":"2008","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3390\/nu7053347","article-title":"Bones of Contention: Bone Mineral Density Recovery in Celiac Disease\u2014A Systematic Review","volume":"7","year":"2015","journal-title":"Nutrients"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e13209","DOI":"10.1111\/aji.13209","article-title":"Exploring undiagnosed celiac disease in women with recurrent reproductive failure: The gluten-free diet could improve reproductive outcomes","volume":"83","author":"Alecsandru","year":"2020","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ajg.2015.192","article-title":"Prevalence of Abnormal Liver Function Tests in Celiac Disease and the Effect of a Gluten-Free Diet in the US Population","volume":"110","author":"Castillo","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients\u2019 adherence to medical recommendations: A quantitative review of 50 years of research","volume":"42","author":"DiMatteo","year":"2004","journal-title":"Med. Care"},{"key":"ref_40","first-page":"2438934","article-title":"A Gluten-Free Diet, Not an Appropriate Choice without a Medical Diagnosis","volume":"2019","author":"Olenick","year":"2019","journal-title":"J. Nutr. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lee, A.R., Wolf, R.L., Lebwohl, B., Ciaccio, E.J., and Green, P.H. (2019). Persistent Economic Burden of the Gluten Free Diet. Nutrients, 11.","DOI":"10.3390\/nu11020399"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ajg.2014.29","article-title":"Patient Perception of Treatment Burden Is High in Celiac Disease Compared with Other Common Conditions","volume":"109","author":"Shah","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clnesp.2020.01.012","article-title":"Can individuals with celiac disease identify gluten-free foods correctly?","volume":"36","author":"Gutowski","year":"2020","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.14309\/ajg.0000000000001139","article-title":"Persistent Villous Atrophy in De Novo Adult Patients with Celiac Disease and Strict Control of Gluten-Free Diet Adherence: A Multicenter Prospective Study (CADER Study)","volume":"116","author":"Salas","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ajcn\/nqx049","article-title":"Determination of gluten consumption in celiac disease patients on a gluten-free diet","volume":"107","author":"Syage","year":"2018","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1365-2036.2008.03669.x","article-title":"Systematic review: Tolerable amount of gluten for people with coeliac disease","volume":"27","author":"Akobeng","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","article-title":"A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease","volume":"85","author":"Catassi","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/00042737-199711000-00013","article-title":"The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population","volume":"9","author":"Mol","year":"1997","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/flgastro-2019-101191","article-title":"How to manage adult coeliac disease: Perspective from the NHS England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease","volume":"11","author":"Baggus","year":"2019","journal-title":"Front. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/apt.12893","article-title":"Histological recovery and gluten-free diet adherence: A prospective 1-year follow-up study of adult patients with coeliac disease","volume":"40","author":"Galli","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2249.2004.02541.x","article-title":"Anti-actin IgA antibodies in severe coeliac disease","volume":"137","author":"Granito","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/B978-0-12-416039-2.00013-6","article-title":"Oral Enzyme Therapy for Celiac Sprue","volume":"502","author":"Bethune","year":"2012","journal-title":"Methods Enzymol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2005.06.017","article-title":"Natural Variation in Toxicity of Wheat: Potential for Selection of Nontoxic Varieties for Celiac Disease Patients","volume":"129","author":"Drijfhout","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.clnu.2013.02.003","article-title":"Evaluation of the safety of ancient strains of wheat in coeliac disease reveals heterogeneous small intestinal T cell responses suggestive of coeliac toxicity","volume":"32","author":"Gregorini","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Colombo, F., Di Lorenzo, C., Biella, S., Bani, C., and Restani, P. (2021). Ancient and Modern Cereals as Ingredients of the Gluten-Free Diet: Are They Safe Enough for Celiac Consumers?. Foods, 10.","DOI":"10.3390\/foods10040906"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Molina, M.D., Gim\u00e9nez, M.J., S\u00e1nchez-Le\u00f3n, S., and Barro, F. (2019). Gluten free wheat: Are we there?. Nutrients, 11.","DOI":"10.3390\/nu11030487"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1073\/pnas.1007773107","article-title":"Effective shutdown in the expression of celiac disease-related wheat gliadin T-cell epitopes by RNA interference","volume":"107","author":"Tollefsen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Guzm\u00e1n-L\u00f3pez, M.H., S\u00e1nchez-Le\u00f3n, S., Mar\u00edn-Sanz, M., Comino, I., Segura, V., Vaquero, L., Rivero-Lezcano, O.M., Pastor, J., Sousa, C., and Vivas, S. (2021). Oral Consumption of Bread from an RNAi Wheat Line with Strongly Silenced Gliadins Elicits No Immunogenic Response in a Pilot Study with Celiac Disease Patients. Nutrients, 13.","DOI":"10.3390\/nu13124548"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo","volume":"134","author":"Anderson","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients with Celiac Disease","volume":"146","author":"Kaukinen","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","article-title":"No Difference between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients with Symptomatic Celiac Disease","volume":"152","author":"Murray","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s10620-017-4687-7","article-title":"Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet","volume":"62","author":"Syage","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Murray, J.A., Syage, J.A., Wu, T.-T., Dickason, M.A., Ramos, A.G., Van Dyke, C., Horwath, I., Lavin, P.T., M\u00e4ki, M., and Hujoel, I. (Gastroenterology, 2022). Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge, Gastroenterology, Epub ahead of print.","DOI":"10.1053\/j.gastro.2022.07.071"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v19.i35.5837","article-title":"Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study","volume":"19","author":"Tack","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a Novel Egg Yolk-Derived Anti-Gliadin Antibody, Is Safe for Patients with Celiac Disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2007.03413.x","article-title":"The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study","volume":"26","author":"Paterson","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","article-title":"A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge","volume":"107","author":"Leffler","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebo-controlled study","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41575-020-00378-1","article-title":"Current and emerging therapies for coeliac disease","volume":"18","author":"Caminero","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2007.05.028","article-title":"Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Patients with Celiac Sprue","volume":"133","author":"Gass","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/jpet.106.104315","article-title":"Effect of Barley Endoprotease EP-B2 on Gluten Digestion in the Intact Rat","volume":"318","author":"Gass","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gut.2006.111609","article-title":"Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: Implications for coeliac disease","volume":"57","author":"Mitea","year":"2008","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00034.2006","article-title":"Highly efficient gluten degradation with a newly identified prolyl endoprotease: Implications for celiac disease","volume":"291","author":"Stepniak","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/apt.13266","article-title":"Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers","volume":"42","author":"Salden","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13100","DOI":"10.1038\/s41598-017-13587-7","article-title":"Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting","volume":"7","author":"Holster","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/jacs.5b08325","article-title":"Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions","volume":"137","author":"Wolf","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"McCarville, J.L., Nisemblat, Y., Galipeau, H.J., Jury, J., Tabakman, R., Cohen, A., Naftali, E., Neiman, B., Halbfinger, E., and Murray, J.A. (2014). 2014BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109972"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/jf205319s","article-title":"In-Vitro and In-Vivo Binding Activity of Chicken Egg Yolk Immunoglobulin Y (IgY) against Gliadin in Food Matrix","volume":"60","author":"Gujral","year":"2012","journal-title":"J. Agric. Food Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2011.10.038","article-title":"The Copolymer P(HEMA-co-SS) Binds Gluten and Reduces Immune Response in Gluten-Sensitized Mice and Human Tissues","volume":"142","author":"Pinier","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101782","DOI":"10.1016\/j.clinre.2021.101782","article-title":"Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Hoilat","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1756283X15616576","article-title":"The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate","volume":"9","author":"Khaleghi","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2012.02.015","article-title":"Larazotide acetate regulates epithelial tight junctions in vitro and in vivo","volume":"35","author":"Gopalakrishnan","year":"2012","journal-title":"Peptides"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1152\/physrev.00003.2008","article-title":"Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer","volume":"91","author":"Fasano","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1021\/bi047747c","article-title":"Equilibrium and Kinetic Analysis of the Unusual Binding Behavior of a Highly Immunogenic Gluten Peptide to HLA-DQ2","volume":"44","author":"Xia","year":"2005","journal-title":"Biochemistry"},{"key":"ref_87","first-page":"e57","article-title":"A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease","volume":"385","author":"Elhence","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1053\/j.gastro.2012.05.051","article-title":"Interactions among Secretory Immunoglobulin A, CD71, and Transglutaminase-2 Affect Permeability of Intestinal Epithelial Cells to Gliadin Peptides","volume":"143","author":"Lebreton","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1053\/j.gastro.2005.07.054","article-title":"Unexpected Role of Surface Transglutaminase Type II in Celiac Disease","volume":"129","author":"Maiuri","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","article-title":"IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease","volume":"578","author":"Abadie","year":"2020","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1073\/pnas.0832466100","article-title":"Transglutaminase 2-\/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells","volume":"100","author":"Szondy","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Paolella, G., Sposito, S., Romanelli, A.M., and Caputo, I. (2022). Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147513"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"B\u00fcchold, C., Hils, M., Gerlach, U., Weber, J., Pelzer, C., Heil, A., Aeschlimann, D., and Pasternack, R. (2022). Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells, 11.","DOI":"10.3390\/cells11101667"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00251-017-0985-7","article-title":"The roles of MHC class II genes and post-translational modification in celiac disease","volume":"69","author":"Sollid","year":"2017","journal-title":"Immunogenetics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nri2670","article-title":"Tissue-mediated control of immunopathology in coeliac disease","volume":"9","author":"Jabri","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1016\/j.bmc.2007.07.001","article-title":"Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease","volume":"15","author":"Xia","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.molimm.2009.10.036","article-title":"Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule","volume":"47","author":"Kapoerchan","year":"2010","journal-title":"Mol. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/mi.2010.44","article-title":"Single-chain recombinant HLA-DQ2.5\/peptide molecules block \u03b12-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: A potential therapy for celiac disease","volume":"4","author":"Huan","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2249.2005.02783.x","article-title":"The immune recognition of gluten in coeliac disease","volume":"140","author":"Ciccocioppo","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/13543784.2018.1438407","article-title":"Investigational drug therapies for coeliac disease\u2014Where to from here?","volume":"27","author":"Haridy","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: A phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"Scheinin","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: A phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","article-title":"PTG-100, an oral \u03b14\u03b27 antagonist peptide: Preclinical development and phase 1 and 2a studies in ulcerative colitis","volume":"161","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Keshav, S., Va\u0148\u00e1sek, T., Niv, Y., Petryka, R., Howaldt, S., Bafutto, M., R\u00e1cz, I., Hetzel, D., Nielsen, O.H., and Vermeire, S. (2013). A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn\u2019s Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060094"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: Vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1136\/gutjnl-2021-326257","article-title":"Immunopathogenesis and environmental triggers in coeliac disease","volume":"71","author":"Levescot","year":"2022","journal-title":"Gut"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10875-012-9849-y","article-title":"Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease","volume":"33","author":"Yokoyama","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0497","article-title":"Celiac Disease Remission with Tofacitinib: A Case Report","volume":"173","author":"Wauters","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e244692","DOI":"10.1136\/bcr-2021-244692","article-title":"Successful novel use of tofacitinib for type II refractory coeliac disease","volume":"15","author":"Grewal","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1053\/gast.2002.31874","article-title":"Successful infliximab treatment for steroid-refractory celiac disease: A case report","volume":"122","author":"Gillett","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00042737-200506000-00012","article-title":"Refractory coeliac disease: Remission with infliximab and immunomodulators","volume":"17","author":"Turner","year":"2005","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.dld.2006.10.017","article-title":"Treatment of life-threatening type I refractory coeliac disease with long-term infliximab","volume":"40","author":"Costantino","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.14309\/crj.2015.25","article-title":"Remission of Refractory Celiac Disease with Infliximab in a Pediatric Patient","volume":"2","author":"Rawal","year":"2015","journal-title":"ACG Case Rep. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1572-0241.2007.01380.x","article-title":"Budesonide in the Treatment of Refractory Celiac Disease","volume":"102","author":"Brar","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ajg.2017.71","article-title":"Open-Capsule Budesonide for Refractory Celiac Disease","volume":"112","author":"Mukewar","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s10620-020-06454-5","article-title":"Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease","volume":"66","author":"Therrien","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/apt.16446","article-title":"Randomised clinical trial: Adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease","volume":"54","author":"Newnham","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10620-008-0501-x","article-title":"Regulatory T-Cell Function Is Impaired in Celiac Disease","volume":"54","author":"Granzotto","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ajg.2011.397","article-title":"Impaired control of effector T cells by regulatory T cells: A clue to loss of oral tolerance and autoimmunity in celiac disease?","volume":"104","author":"Hmida","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jaci.2017.02.015","article-title":"Circulating gluten-specific FOXP3+CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease","volume":"140","author":"Cook","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15907","DOI":"10.1038\/srep15907","article-title":"Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens","volume":"5","author":"Grimm","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: Two randomised, double-blind, placebo-controlled phase 1 studies","volume":"2","author":"Goel","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Daveson, A.J., Jones, D.M., Gaze, S., McSorley, H., Clouston, A., Pascoe, A., Cooke, S., Speare, R., Macdonald, G.A., and Anderson, R. (2011). Effect of Hookworm Infection on Wheat Challenge in Celiac Disease\u2014A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017366"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2017.11.018","article-title":"Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study","volume":"26","author":"Daveson","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.15435","article-title":"Randomised clinical trial: A placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease","volume":"50","author":"Truitt","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e00274","DOI":"10.14309\/ctg.0000000000000274","article-title":"Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease","volume":"11","author":"Croese","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/gut.2005.079129","article-title":"A proof of concept study establishing Necator americanus in Crohn\u2019s patients and reservoir donors","volume":"55","author":"Croese","year":"2006","journal-title":"Gut"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease","volume":"135","author":"Croese","year":"2015","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:58:40Z","timestamp":1760119120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":131,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24020945"],"URL":"https:\/\/doi.org\/10.3390\/ijms24020945","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]}}}